DBV Technologies SA · EURONEXT:DBV

DBV Technologies SA — Non-Deal Roadshow (January 2013)

32 slides from DBV Technologies SA's roadshow presentation, January 2013

  1. Slide 1: The Next Leader in the Treatment of Allergies

    THE NEXT LEADER IN THE TREATMENT OF ALLERGIES January 2013

  2. Slide 2: Disclaimer

    Disclaimer This document contains information on DBV Technologies’ markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from DBV Technologies’ own estimates. Investors should not base their investment decision on

  3. Slide 3: DBV Management Team

    DBV Management Team Pierre-Henri Benhamou, M.D. Chairman and CEO Medical Doctor specialized in Paediatric Gastroenterology Co-founded DBV in 2002 CSO and CEO position David Schilansky Chief Financial Officer 3 years of experience in the M&A Department of UBS 3 years of experience at Thomson Technico

  4. Slide 4: DBV's Fact Sheet

    DBV’s Fact Sheet Shareholders* Key information/ data Listed on Euronext Paris (DBV.PA or DBV FP) Float Sofinnova c.$150 m market cap 25.3 % 27.7 % $50 m net cash position as of Dec 31, 2012 Management 4.8 % Established in 2002 Shire 4.3 % InnoBio Launched first diagnostic product in 2004 13.3 % Lund

  5. Slide 5: DBV is focusing first on allergies, a fast growing disease worldwide

    DBV is focusing first on allergies, a fast growing disease worldwide Source: Bousquet et al. 1999 5

  6. Slide 6: Food allergy is a large unmet medical need

    Food allergy is a large unmet medical need, with more than 500 million people worldwide All allergic diseases in children are increasing (food allergies, environmental diseases, allergies, asthma & eczema) 4 out of every 100 children were reported to have a food allergy 40% of food allergic children

  7. Slide 7: Specific Immunotherapy is a known, well established causal therapy

    Specific Immunotherapy (‘desensitization’) is a known, well established causal therapy Specific Immunotherapy is the only established causal therapy recognized by the WHO Specific Immunotherapy by subcutaneous or sublingual administration may lead the allergen to enter into the bloodstream Current t

  8. Slide 8: Viaskin opens a new field to Specific Immunotherapy

    Viaskin® opens a new field to Specific Immunotherapy PEANUT Life-threatening food allergy in children and adults MILK First food allergy developed by children HOUSE DUST MITES First respiratory allergy developed by children A high need of a safe enough standardised pharmaceutical treatment able to a

  9. Slide 9: Viaskin: the first pharmaceutical treatment safe enough

    Viaskin: the first pharmaceutical treatment safe enough… Large US phase Ib study Safety The skin gateway to the immune system History of use in anaphylactic patients Pilot study in milk Efficacy Interim results for phase II (‘Arachild’) VIPES and CoFAR studies 9

  10. Slide 10: Standardized enough to address food and young children's allergies

    … and standardized enough to be able to address food and young children’s allergies 1 Viaskin® a day, ready-to-use and patient friendly The skin gateway to the immune system Applied to intact skin on the arm or back over a 1 to 3 year period Non invasive, well tolerated For both adults and children

  11. Slide 11: Partnering opportunities

    Partnering opportunities Europe DBV marketing of Viaskin® Japan Viaskin® North America Development and Viaskin® platform commercialisation rights Commercialisation rights out-licensing out-licensing UNIGE China Viaskin® Viaskin® WW partnership for Development and vaccination commercialisation rights

  12. Slide 12: Viaskin opens a large untapped market

    Viaskin opens a large untapped market: no existing pharmaceutical treatment or development efforts VIASKIN® USA and EUR-27 VIASKIN® Milk VIASKIN® HDM Peanut Target population 4.1 millions 1.5 million 5.7 millions 11.3 millions Potential peak sales $2.0 bn $0.5 bn $2.9 bn $5.4 bn 12

  13. Slide 13: Viaskin: an aggressive development program with significant milestones

    Viaskin®: an aggressive development program with significant milestones already achieved

  14. Slide 14: Viaskin: a user friendly treatment

    Viaskin: a user friendly treatment… 1 2 3 Adhesive Dry layer of Polarized Crown Allergenic Proteins Polymer Water Accumulation and Natural Epidermis Epidermis Condensation Water loss – SKIN SKIN Hydration of Dermis Dermis Skin Electrostatic patch Condensation chamber Hydration 4 5 6 Interaction Inte

  15. Slide 15: Originating from a major scientific discovery

    …originating from a major scientific discovery… Viaskin® delivers the allergen through intact skin with no passage in the blood Allergen (OVA-A488) Epidermis Dermis 15

  16. Slide 16: With a proven mechanism of action

    …with a proven mechanism of action 16

  17. Slide 17: Exclusive intra-cellular passage

    Exclusive intra-cellular passage… % of cells that have uptaken the allergen 80 60 A488+ (%) 40 20 0 0 6 24 48 72 Period (hours) 17

  18. Slide 18: To the lymph node

    … to the lymph node… Epidermis Dermis Lymph node 4 4 0,4 A488+ DC (% of total) A488+ DC (% of total) A488+ DC (% of total) 3 3 0,3 2 2 0,2 1 1 0,1 0 0 0 0 6 24 0 6 24 48 72 0 6 24 48 72 Time (hours) Time (hours) Time (hours) 18

  19. Slide 19: Without any passage into the blood stream

    … without any passage into the blood stream 150 125 0h Ara h 1 (ng/ml) 100 2h 75 8h 24h 50 48h 25 0 Intact SC skin injection 19

  20. Slide 20: Proven safety profile in a large phase Ib study

    Proven safety profile in a large phase Ib study Phase Ib 100 randomized peanut allergic subjects in 5 US centers Adults and children ranging from non-severe to anaphylactic Study start in July 2010 and ended in February 2012 Mild Adverse Events incidence comparable to placebo group No SAEs Excellent

  21. Slide 21: Early proof of efficacy

    Early proof of efficacy Arachild - Peanut Pilot study - Milk 54 randomized severely allergic children 19 randomized severely allergic children EVOLUTION OF PATIENTS ON THERAPY Patients able to drink Highly significant a glass of milk after 3 Volume of Milk tolerated before symptoms appear (ml) 100 I

  22. Slide 22: An aggressive development plan underway

    An aggressive development plan underway Pre-clin Phase I Phase II Phase III Filing Viaskin® Peanut (VIPES) 2012 2014 2016 Viaskin® Milk 2013 2014 2016 Viaskin® HDM 2014 2015 2017 2019 Diallertest 2012 2 ACADEMIC STUDIES Arachild (AP-HP) 2011 Peanut (COFAR-NIH) 2013 A global clinical program for worl

  23. Slide 23: Example of Study design in peanut allergy

    Example of Study design in peanut allergy Placebo Phase II, France, 100 µg Arachild Pediatric, 54 patients 6 months DBPCFC DBPCFC DBPCFC DBPCFC DBPCFC 12 months 18 months 36-42 months Placebo OLFUS Phase II, 50 µg Optimal dose Transcontinental, VIPES 100 µg Adult & Pediatric, 220 patients 250 µg 12

  24. Slide 24: By end 2015, Viaskin Peanut will benefit from more than 1100 patient-years

    By end 2015, Viaskin Peanut will benefit from more than 1100 patient-years of treatment 2017 2000 MAA filing 1800 2016 1600 BLA filing 1400 800 1200 500 Phase III 200 1000 COFAR 6 200 200 200 VIPES 800 Arachild 0 600 125 605 605 605 400 0 50 385 200 165 0 149 162 162 162 162 0 41 95 0 2011 2012 2013

  25. Slide 25: Viaskin: high barriers to entry for a highly versatile technology

    Viaskin®: high barriers to entry for a highly versatile technology

  26. Slide 26: A complex and 100% proprietary technology creating high barriers to entry

    A complex and 100% proprietary technology creating high barriers to entry Established GMP manufacturing process Manufacturing tool fully engineered & designed by DBV µg) of API - Deposits very small & precise quantities (µ devoid of adjuvants on Viaskin Manufacturing process allows final product to

  27. Slide 27: Full worldwide patents on the method, technology, manufacturing processes and applications

    Full worldwide patents on the method, technology, manufacturing processes and applications Allergy Deposit Peanut Eczema ELECTROSPRAY Eosinophilic esophagitis EPIT Epicutaneous Core technology Immunotherapy VIASKIN® I: Dry patch Architecture, electrostatic forces, adhesive crown VIASKIN® II: APPLICA

  28. Slide 28: Conclusion

    Conclusion

  29. Slide 29: A new allergy treatment endorsed by the scientific community

    A new allergy treatment endorsed by the scientific community A world-class Scientific Board of Advisors Peers recognition 1 W. ZEIGER 2 J. SPERGEL 3 F. ADKINSON 3 YAMO DENIZ Clinical Professor in Professor of Professor of VP, Global Head of the Department of Pediatrics at the Medicine at Johns Clini

  30. Slide 30: A versatile technology platform

    A versatile technology platform Because Viaskin is… …Viaskin can target… Safe & efficacious All types of allergies Ready-to-use and user-friendly Most dangerous allergies Single dose and standardised Young children allergies Non invasive Stocked at room temperature Vaccines 30

  31. Slide 31: Appendix

    Appendix

  32. Slide 32: A landmark pilot efficacy study in Cow's milk allergy

    A landmark pilot efficacy study in Cow’s milk allergy EVOLUTION OF PATIENTS ON THERAPY EVOLUTION OF PATIENTS IN PLACEBO GROUP, and then ON THERAPY* Volume of Milk tolerated before symptoms appear (ml) Patients able to drink a glass 100 67,1 100* of milk after 3 months 64,6 47,1 47 25,5 27,1 27,1 20

DBV Technologies — Non-Deal Roadshow (January 2013) on 6ix